Stay updated on JNJ-67856633 and Ibrutinib Combination in B-cell NHL and CLL Clinical Trial
Sign up to get notified when there's something new on the JNJ-67856633 and Ibrutinib Combination in B-cell NHL and CLL Clinical Trial page.

Latest updates to the JNJ-67856633 and Ibrutinib Combination in B-cell NHL and CLL Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov site revision identifier changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoChange DetectedThe record describes a Phase 1b study of JNJ-67856633 with ibrutinib for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. It includes the study’s completed status, eligibility criteria, participating locations, treatment plan, and outcome measures.SummaryDifference44%

- Check15 days agoChange DetectedThe site revision identifier was updated from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check29 days agoChange DetectedA sitewide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology, and the site revision label advances from v3.7.1 to v3.7.2. The study page still displays a 403 error.SummaryDifference1%

- Check43 days agoChange DetectedThe site's displayed revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, indicating access to the record is blocked. This does not modify the underlying study data but prevents viewing the content.SummaryDifference16%

Stay in the know with updates to JNJ-67856633 and Ibrutinib Combination in B-cell NHL and CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the JNJ-67856633 and Ibrutinib Combination in B-cell NHL and CLL Clinical Trial page.